I, Jason Napodano, CFA, hereby certify that all views expressed on this or any other blog, or in my Twitter, accurately reflect my personal views about the subject securities. I believe the information used for the creation of articles for this or any other blog or tweets has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed on this or any other blog or via Twitter are subject to change without notice.
At times, I submit articles under Seeking Alpha's Premium or Pro programs, which pays on a per click or set rate per article. I receive compensation from Google Adsense for advertising seen on this blog. At times, I own stock in companies about which I publish reports or articles. All reports or articles will always disclose my position if I am long or short the stock. Readers of this blog can assume that no disclosed position means I am neither long nor short the common stock.
REFERRALS AND FEES FOR SERVICE
I hold no FINRA or SEC securities licenses. I do not provide nor have I received compensation for investment banking services on the securities covered on this blog or via my Twitter. I do not expect to receive compensation for investment banking services from issues covered by this blog or via my Twitter.
BioNap Consulting, Inc. may have been paid a fee by some of the companies featured on this blog. These fees include, but are not limited to, introductions to research analysts, brokers, institutional investors and money managers, providing strategic advisory services with respect to investor relations, writing white papers or informational articles, providing due diligence services such as market research and valuation / fairness opinions for licensing or M&A transactions, and sponsored research articles seen on this blog. Since I may have been compensated for these services, investors should understand this potential conflict of interest and evaluate the information on this blog with that in mind. BioNap encourages investors to always perform their own independent analysis.
The purpose of this blog is to provide fair and accurate information on subject companies contained herein. My analysis is designed to explain the diseases, the science behind the drugs, and the market opportunity so that investors can make informed decisions. My articles will often cover clinical data where I am extrapolating to commercial use and implying success or failure, but keep in mind these are my opinions only, and investors should perform personal due diligence to back-up or refute my work. For investor due diligence and intelligence services, companies hire BioNap Consulting and pay fees in cash that typically range between two thousand and five thousand dollars per month. Past and/or current clients of BioNap include are available upon request.
This blog is for informational purposes only. Articles and Tweets are based on publicly available information only, and obtained from sources I believe to be reliable, but I cannot guarantee to be accurate nor do I purport to be complete. Because of individual objectives, articles or Tweets should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk, and investment in biotechnology stocks involves significant risk. You can lose money by trading or investing in stocks mentioned on this blog or any other blog, or my Twitter! Investors should be aware of these risks and consult a certified financial planner (CFP) before making investment decisions. I am not a CFP, and I do not recommend the purchase or sale of any securities based on information found only this website or my Twitter.
By visiting this blog or my Twitter, investors understand and assume full responsibility for this disclaimer. Any opinions expressed on this blog or via my Twitter are subject to change without notice. Articles or Tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities mentioned herein. Additional information is available upon request.
DISCLAIMER FOR CLIENTS
BioNap may have spoken to the management of companies featured on this website to obtain information for articles contained herein. At times, BioNap may interview management and post the transcript of that conversation on this blog. Investors should be aware that certain statements contained in articles or transcribed interviews may be “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the company’s beliefs and assumptions.
Investors should understand, the company’s actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the company’s Annual Reports and MD&A filed with the United States Securities and Exchange Commission (SEC). Subsequent events and developments may cause these forward-looking statements to change. BioNap specifically disclaims any obligation or intention to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
WE ARE NOT AN INVESTMENT ADVISOR
BioNap Consulting, Inc. does not provide specific, personalized investment advice! BioNap is not a registered investment advisor or an investment bank. We hold no FINRA or SEC securities licenses and we are not a regulated entity by the U.S. Securities and Exchange Commission. BioNap articles do not contain any rating or recommendation.
Articles may have target prices. I do my best to explain fully how these targets are derived. Opinions and price targets reported on Twitter are associated with articles found or linked within this blog, or articles published on websites such as Seeking-Alpha, Benzinga, or WhoTrades, among others.
Articles, where BioNap has provided intelligence, due diligence, or advisory services for a fee to the subject company, may include target valuation models and market research suggesting things like peak sales opportunity or projected market share. Articles may also imply potential upside based on fundamental or valuation analysis. However, BioNap expressly cautions investors on the opinions found in reports or articles on subject companies where BioNap has been paid any fee.
To learn more about me, visit the About Me tab above.
Jason Napodano, CFA